Mesenchymal stem cells as a treatment for neonatal ischemic brain damage

Velthoven, Cindy T. J. van; Kavelaars, Annemieke; Heijnen, Cobi J.

doi:10.1038/pr.2011.64

Cited by 132 publications

(94 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In preclinical laboratories, BMSCs have been considered a promising cell source for treatment of many diseases, including ischemic stroke (15,63), traumatic brain injury (60), intracerebral hemorrhage (62), subarachnoid hemorrhage (31), spinal cord injury (33), and other neurodegenerative disorders (2,29,39,42). However, most preclinical and all clinical studies have been performed on adult animals or humans, and only a few reports have studied stem cell therapy in neonatal stroke models (52,56,59,61). Those laboratories show great promise for cellular therapy using core blood stem cells or BMSCs to provide enhanced trophic support and an enriched microenvironment in the damaged developing brain (11,32,57).…”

Section: Discussionmentioning

confidence: 99%

“…Bone marrowderived mesenchymal stem cells (BMSCs) have been considered as an appropriate cell source for treatment of some neonatal disease models, including perinatal asphyxia, hypoxic-ischemic brain injury, and cerebral palsy (17,43,44,56,58). However, whether BMSC therapy may have a long-term benefit to prevent or reverse neurological and neuropsychiatric problems is not well established (12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Wei

Ferdinand

et al. 2015

Cell Transplant

View full text Add to dashboard Cite

Neonatal stroke is a major cause of mortality and long-term morbidity in infants and children. Currently, very limited therapeutic strategies are available to protect the developing brain against ischemic damage and promote brain repairs for pediatric patients. Moreover, children who experienced neonatal stroke often have developmental social behavior problems. Cellular therapy using bone marrow mesenchymal stem cells (BMSCs) has emerged as a regenerative therapy after stroke. In the present investigation, neonatal stroke of postnatal day 7 (P7) rat pups was treated with noninvasive and brain-specific intranasal delivery of BMSCs at 6 h and 3 days after stroke (1 × 10 6 cells/animal). Prior to transplantation, BMSCs were subjected to hypoxic preconditioning to enhance their tolerance and regenerative properties. The effects on regenerative activities and stroke-induced sensorimotor and social behavioral deficits were specifically examined at P24 of juvenile age. The BMSC treatment significantly reduced infarct size and blood-brain barrier disruption, promoted angiogenesis, neurogenesis, neurovascular repair, and improved local cerebral blood flow in the ischemic cortex. BMSC-treated rats showed better sensorimotor and olfactory functional recovery than saline-treated animals, measured by the adhesive removal test and buried food finding test. In social behavioral tests, we observed functional and social behavioral deficits in P24 rats subjected to stroke at P7, while the BMSC treatment significantly improved the performance of stroke animals. Overall, intranasal BMSC transplantation after neonatal stroke shows neuroprotection and great potential as a regenerative therapy to enhance neurovascular regeneration and improve functional recovery observed at the juvenile stage of development.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Wei

Ferdinand

et al. 2015

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Probably, the banking and followed by clinical application of mixed population of maternal and fetal MSCs will potentially lead to a greater and interesting therapeutic effect. Further research is needed to verify this hypothesis [23][24][25][26][27][28][29][30][31].…”

Section: A B C D E F G Hmentioning

confidence: 99%

Isolation and Characteristics of Mesenchymal Stromal Cells from Different Parts of Placenta

Semenova¹,

Mrowiec²,

Machaj³

et al. 2017

J Stem Cell Res Ther

View full text Add to dashboard Cite

“…So little is currently known about cells posttransplantation; whether cells end up in the brain may ultimately be of little significance to their ability to improve outcome in stroke (although their being dispersed in unknown regions of the recipient would certainly complicate imaging due to, for example, positioning of the coil in MRI). Indeed, while many studies show stem cell homing to the brain after stroke, 19,112 it has been shown that transplanted cells still improve recovery in rats treated with bone marrow stem cells after middle cerebral artery occlusion, despite the majority of these cells ending up in peripheral organs (including the lungs, spleen, and liver). 113 Furthermore, where one route of administration is preferable to another for stem cells from a particular source, imaging will-and does-help identify this.…”

Section: Translating Cell Tracking Technologies To the Clinicmentioning

confidence: 99%

Cell Tracking Technologies for Acute Ischemic Brain Injury

Gavins

Smith

2015

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Stem cell therapy has showed considerable potential in the treatment of stroke over the last decade. In order that these therapies may be optimized, the relative benefits of growth factor release, immunomodulation, and direct tissue replacement by therapeutic stem cells are widely under investigation. Fundamental to the progress of this research are effective imaging techniques that enable cell tracking in vivo. Direct analysis of the benefit of cell therapy includes the study of cell migration, localization, division and/or differentiation, and survival. This review explores the various imaging tools currently used in clinics and laboratories, addressing image resolution, long-term cell monitoring, imaging agents/isotopes, as well as safety and costs associated with each technique. Finally, burgeoning tracking techniques are discussed, with emphasis on multimodal imaging.

show abstract

Mesenchymal stem cells as a treatment for neonatal ischemic brain damage

Cited by 132 publications

References 85 publications

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Intranasal Delivery of Bone Marrow Mesenchymal Stem Cells Improved Neurovascular Regeneration and Rescued Neuropsychiatric Deficits after Neonatal Stroke in Rats

Isolation and Characteristics of Mesenchymal Stromal Cells from Different Parts of Placenta

Cell Tracking Technologies for Acute Ischemic Brain Injury

Contact Info

Product

Resources

About